hydroxychloroquine and nusinersen

hydroxychloroquine has been researched along with nusinersen in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Adams, D; Attarian, S; Cintas, P; Desguerre, I; Laforet, P; Molon, A; Pereon, Y; Pisella, LI; Salort-Campana, E; Solé, G; Stojkovic, T; Tiffreau, V; Wahbi, K	1

Other Studies

1 other study(ies) available for hydroxychloroquine and nusinersen

Article	Year
Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. Revue neurologique, 2020, Volume: 176, Issue:6 Topics: alpha-Glucosidases; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Bacterial Agents; Antimalarials; Azithromycin; Betacoronavirus; Cardiorespiratory Fitness; Coronavirus Infections; COVID-19; Emergency Treatment; France; Glycogen Storage Disease Type II; Hospitalization; Humans; Hydroxychloroquine; Immune System Diseases; Immunoglobulins, Intravenous; Immunosuppressive Agents; Muscular Atrophy, Spinal; Neuromuscular Diseases; Oligonucleotides; Pandemics; Physical Therapy Modalities; Pneumonia, Viral; Prognosis; RNA, Small Interfering; SARS-CoV-2; Steroids; Withholding Treatment	2020

Article

Year

Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.

Revue neurologique, 2020, Volume: 176, Issue:6

Topics: alpha-Glucosidases; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Bacterial Agents; Antimalarials; Azithromycin; Betacoronavirus; Cardiorespiratory Fitness; Coronavirus Infections; COVID-19; Emergency Treatment; France; Glycogen Storage Disease Type II; Hospitalization; Humans; Hydroxychloroquine; Immune System Diseases; Immunoglobulins, Intravenous; Immunosuppressive Agents; Muscular Atrophy, Spinal; Neuromuscular Diseases; Oligonucleotides; Pandemics; Physical Therapy Modalities; Pneumonia, Viral; Prognosis; RNA, Small Interfering; SARS-CoV-2; Steroids; Withholding Treatment

2020